NSPR (InspireMD) FFO


NSPR InspireMD Inc NSPR
35 GF Score
Price $0.70
GF Value $1.78
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD FFO?

FFO (Funds from operations) only applies to REITs.

NSPR
35GF Score
InspireMD Inc NSPR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InspireMD (NSPR) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of $0.70 is trading 60.7% below its estimated GF Value™ of $1.78. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for NSPR:

  • FFO:
  • GF Value™: $1.78 vs. price of $0.70 (60.7% below fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the NSPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges II2:Germany
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
35GF Score

Get the complete analysis for NSPR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$1.78
GF Value